Tenofovir treatment duration predicts proteinuria in a multiethnic united states cohort of children and adolescents with perinatal HIV-1 infection

Pediatric Infectious Disease Journal

Volumn 32, Issue 5, 2013, Pages 495-500

  Purswani, Murli ^a   Patel, Kunjal ^b,c   Kopp, Jeffrey B ^d   Seage III, George R ^b,c   Chernoff, Miriam C ^c   Hazra, Rohan ^e   Siberry, George K ^e   Mofenson, Lynne M ^e   Scott, Gwendolyn B ^f   Van Dyke, Russell B ^g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Chronic kidney disease; Nephrotoxicity; Proteinuria; Proximal tubules; Tenofovir; Urine protein creatinine ratio

Indexed keywords

CREATININE; PROTEIN; TENOFOVIR;

ARTICLE; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PERINATAL INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SCHOOL CHILD; TREATMENT DURATION; UNITED STATES; URINALYSIS;

ADENINE; ADOLESCENT; AFRICAN AMERICANS; ANTI-HIV AGENTS; CHILD; COHORT STUDIES; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; ORGANOPHOSPHONATES; PREVALENCE; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; STATISTICS, NONPARAMETRIC; UNITED STATES;

EID: 85029548837     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827f4eff     Document Type: Article

References (41)

1. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 11, 2011; pp 1-268. Available at: http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines,pdf. Accessed March 5, 2012.
2. Hazra R, Gafhi RI, Maldarelli F, et al. Tenofovir disoproxil flimarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116:e846-e854.
3. Delia Negra MD, de Carvalho AP, de Aquino MZ, et al. A randomized study of tenofovir disoproxil flimarate in treatment-experienced human immunodeficiency virus-1 infected adolescents. Pediatr Infect Dis J. 2012; 31:469-473.
4. Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil flimarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24:525-534.
5. U.S. Food and Drug Administration. Label and approval history for Viread, NDA No. 021356. January 18, 2012. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/021356s0381bl.pdf. Accessed March 5, 2012.
6. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil flimarate vs. a thymidine analogue-containing regimen in antiretroviralnaive patients. AIDS. 2008;22:2155-2163.
7. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil flimarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37:1489-1495.
8. Izzedine H, Hulot JS, Vittecoq D, et al.; Study 903 Team. Long-term renal safety of tenofovir disoproxil flimarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743-746.
9. Szczech LA. Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context. J Infect Dis. 2008;197:7-9.
10. Quiros-Roldan E, Amadasi S, Paraninfo G, et al. The impact of gender and anchor drugs on TDF renal toxicity. J Acquir Immune Defic Syndr. 2010;55:e11-e12.
11. Gallant JE, Staszewski S, Pozniak AL, et al.; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
12. Goicoechea M, Liu S, Best B, et al.; California Collaborative Treatment Group 578 Team. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102-108.
13. Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy Kidney Int. 2010;78:1060-1063.
14. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78:1171-1177.
15. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
16. Rodriguez-Növoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacoge-netic study. Clin Infect Dis. 2009;48:e108-e116.
17. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689-696.
18. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005;6:284-290.
19. Viganô A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig. 2007;27:573-581.
20. Viganô A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil flimarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig. 2011; 31:407-445.
21. Andiman WA, Chernoff MC, Mitchell C, et al.; PACTG iDACS 617 Study Team. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28:619-625.
22. Soler-Palacfn P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25:171-176.
23. Pontrelli G, Cotugno N, Amodio D, et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil flimarate and protease inhibitors. BMC Infect Dis. 2012;12:18.
24. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.
25. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stats 11. 2002;246:1-190.
26. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832-1843.
27. Chaparro AI, Mitchell CD, Abitbol CL, et al. Proteinuria in children infected with the human immunodeficiency virus. J Pediatr. 2008;152:844-849.
28. Esezobor CI, Iroha E, Onifade E, et al. Prevalence of proteinuria among HIV-infected children attending a tertiary hospital in Lagos, Nigeria. J Trop Pediatr. 2010;56:187-190.
29. Strauss J, Abitbol C, Zilleruelo G, et al. Renal disease in children with the acquired immunodeficiency syndrome. N EnglJ Med. 1989;321:625-630.
30. Pardo V, Meneses R, Ossa L, et al. AIDS-related glomerulopathy: occurrence in specific risk groups. Kidney Int. 1987;31:1167-1173.
31. Lin CY, Sheng CC, Chen CH, et al. The prevalence of heavy proteinuria and progression risk factors in children undergoing urinary screening. Pediatr Nephrol. 2000;14:953-959.
32. Murakami M, Yamamoto H, Ueda Y, et al. Urinary screening of elementary and junior high-school children over a 13-year period in Tokyo. Pediatr Nephrol. 1991;5:50-53.
33. Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004;18:541-546.
34. Atta MG. Diagnosis and natural history of HIV-associated nephropathy. Adv Chronic Kidney Dis. 2010;17:52-58.
35. Abitbol CL, Strauss J, Zilleruelo G, et al. Validity of random urines to quan-titate proteinuria in children with human immunodeficiency virus nephropathy. Pediatr Nephrol. 1996;10:598-601.
36. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867-875.
37. Kelly MD, Gibson A, Bartlett H, et al. Tenofovir-associated proteinuria. AIDS. 2013;27:479-481.
38. Rodriguez-Növoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Safi 2010;9:545-559.
39. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55:78-81.
40. Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302-309.
41. Hegde S, Singh C, Ohare B. HIV-associated nephropathy in the setting of maximal virologie suppression. Pediatr Nephrol. 2011;26:973-977. Human Development